Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares at $45.81 ($238K) on 2026-04-17, disclosed to the SEC on 2026-04-21.
Scheduled sale ($238k) by CHIEF MEDICAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.81 | 140 | $6K | 2.7% |
| 2 | $47.39 | 2,419 | $115K | 48.1% |
| 3 | $48.06 | 2,441 | $117K | 49.2% |
| Total | $47.67 avg | 5,000 | $238K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $263K | — | Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-05-20 | $199K | — | Filing → |